Expansion into UK marks company’s third international subsidiary.
Flatiron Health, an oncology-focused RWD technology company, has partnered with the Leeds Teaching Hospitals NHS Trust (LTHT), one of largest acute hospital trusts in Europe. The entry into the United Kingdom marks a major milestone in Flatiron’s expansion.
Flatiron International has subsidiaries already in Japan and Germany. Each partners with hospitals and health networks in RWD collaborations through Flatiron's local teams and infrastructure, ensuring that strict legal and regulatory requirements are met in all locations. The goal is to produce more top-quality oncology datasets for use by Flatiron’s hospital and health network partners in research collaborations and under license—with specific terms and conditions—to biopharma companies, to accelerate cancer research.
“Each Flatiron International partnership is designed to help local healthcare providers and partners generate and utilize high-quality RWD to advance oncology research and care,” said Nathan Hubbard, SVP, Flatiron’s head of corporate development and Flatiron International. He noted that the agreement was approved by the NHS Health Research Authority.
Reference: Flatiron Health Announces New Partnership in the UK, June 20, 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.